Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 2015

View Archived Issues

Dimension Therapeutics hemophilia gene therapy candidate receives FDA orphan designation

Fostamatinib wins U.S. orphan status for immune thrombocytopenic purpura

Sodium 2-hydroxylinoleate named U.S. orphan drug for neuroblastoma

FDA grants nivolumab orphan status for glioblastoma

Amgen reports development of aminopyridine PDE10A inhibitors

MicuRx's MRX-I shows comparable clinical cure rate to linezolid in phase II trial

Amicus Therapeutics to acquire Scioderm

Sun BioPharma to start phase I trial of SBP-101 in pancreatic ductal adenocarcinoma

Portage to advance PPL-003 to IND application for dry eye and uveitis

Study indicates that RAGE is a risk factor for developing heart failure

Juventas reports 1-year findings from phase II STOP-HF trial

Allergan completes acquisition of Naurex

FDA accepts Empliciti BLA for priority review

Trevena reports data from phase IIb study of TRV-130 in acute postoperative pain

Bristol-Myers Squibb reports HIV integrase inhibitors

Takeda discloses GPR6 modulators

Polyphor advances inhaled POL-6014 for lung diseases to phase I

Karus discloses PI3K inhibitors

CSIR divulges tricyclic antineoplastics

Celon Pharma discloses JAK-2 inhibitors

Merck & Co. discloses c-Met inhibitors

Encouraging results reported for Vaxart's oral influenza vaccine

Zecuity now available in the U.S.

Ring vaccination trial of Ebola virus vaccine VSV-EBOV extended to Sierra Leone

Strensiq launched in Japan for hypophosphatasia

FDA grants fast track designation to Flexion's FX-006 for knee osteoarthritis pain

Promising topline results from phase III STRUCTURE trial of romosozumab

FDA approves Augment Bone Graft

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...